¼¼°èÀÇ ´ÙÁß¾Ï Á¶±â ¹ß°ß ½ÃÀå
Multi Cancer Early Detection
»óǰÄÚµå : 1787194
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 214 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ´ÙÁß¾Ï Á¶±â ¹ß°ß ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 26¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

¼¼°èÀÇ ´ÙÁß¾Ï Á¶±â ¹ß°ß ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 11¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ºÐ¼® ±â°£ 2024-2030³â¿¡ CAGR 15.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 26¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ À¯ÀüÀÚ ÆÐ³Î & LDT´Â CAGR 13.8%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 14¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾×ü »ý°Ë ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 18.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 9,600¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 20.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ´ÙÁß¾Ï Á¶±â ¹ß°ß ½ÃÀåÀº 2024³â¿¡ 2¾ï 9,600¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 5¾ï 5,680¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ 2024-2030³â CAGRÀº 20.4%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 11.7%¿Í 13.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 12.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ´ÙÁß¾Ï Á¶±â ¹ß°ß ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

´ÙÁß¾Ï Á¶±â ¹ß°ßÀº ¾Ï Áø´ÜÇÐÀ» ¾î¶»°Ô ÀçÆíÇϰí Àִ°¡?

¾Ï Áø´Ü¿¡ Çõ¸íÀ» °¡Á®¿Ã ȹ±âÀûÀÎ ±â¼úÀÎ ´ÙÁß¾Ï Á¶±â ¹ß°ß(MCED)ÀÇ µîÀåÀ¸·Î ¾Ï ¹ß°ßÀÇ »óȲÀÌ ±Þº¯Çϰí ÀÖ½À´Ï´Ù. À¯¹æ¾ÏÀÇ À¯¹æÃÔ¿µ¼ú, ´ëÀå¾ÏÀÇ ´ëÀå³»½Ã°æ °Ë»ç µî ÀϺΠ¾Ç¼º Á¾¾ç¸¸À» ´ë»óÀ¸·Î ÇÏ´Â ±âÁ¸ ¾Ï °ËÁø°ú´Â ´Þ¸® MCED °Ë»ç´Â ÷´Ü À¯Àüü, ÈļºÀ¯Àüü, ´Ü¹éÁúüÇÐ ¹ÙÀÌ¿À¸¶Ä¿¸¦ Ȱ¿ëÇÏ¿© ÇÑ ¹øÀÇ °Ë»ç·Î ¿©·¯ ¾ÏÁ¾À» µ¿½Ã¿¡ °ËÃâÇÕ´Ï´Ù. ÀÌ´Â Ç÷¾× »ùÇÿ¡¼­ ¼øÈ¯ Á¾¾ç DNA(ctDNA), RNA ½Ã±×´Ïó ¹× ±âŸ ºÐÀÚ º¯È­¸¦ ºÐ¼®ÇÏ´Â ¾×ü »ý°ËÀ» ÅëÇØ ÀÌ·ç¾îÁý´Ï´Ù. ¾ÏÀº ¿©ÀüÈ÷ Àü ¼¼°è »ç¸Á ¿øÀÎ 1À§ÀÎ ¸¸Å­ Á¶±â ¹ß°ßÀº »ýÁ¸À²À» ³ôÀÌ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, ¾Ï °ü·Ã »ç¸ÁÀÇ »ó´ç ºÎºÐÀ» Â÷ÁöÇÏ´Â °ÍÀº ¸»±â Áø´ÜÀ̸ç, ÀÌ´Â Á¶±â, ºñħ½ÀÀû, Á¾ÇÕÀûÀÎ ½ºÅ©¸®´× ¼Ö·ç¼ÇÀÇ ½Ã±ÞÇÑ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML) ¾Ë°í¸®ÁòÀÌ ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°À» Çâ»ó½ÃÅ´À¸·Î½á MCED °Ë»ç´Â ÀÌÁ¦ ±× ¾î´À ¶§º¸´Ù Á¤È®Çϰí, È®À强ÀÌ ¶Ù¾î³ª¸ç, Á¢±Ù¼ºÀÌ ³ô¾ÆÁ³½À´Ï´Ù. ÀϺΠ»ý¸í°øÇÐ ±â¾÷ ¹× ¿¬±¸±â°üµéÀº ´ë±Ô¸ð ÀÓ»ó½ÃÇèÀ» ÅëÇØ ÀÌ·¯ÇÑ °Ë»ç¸¦ °ËÁõÇÏ´Â µ¥ Å« ÁøÀüÀ» ÀÌ·ç¾úÀ¸¸ç, Áõ»óÀÌ ³ªÅ¸³ª±â Àü¿¡ ¾ÏÀ» ½Äº°ÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ» ÀÔÁõÇß½À´Ï´Ù. ¸»±â ¾Ï Áø´ÜÀÇ ºÎ´ãÀ» ÁÙÀ̰í ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµÇ¸é¼­ ÀÇ·á°è, ÅõÀÚÀÚ, ±ÔÁ¦ ´ç±¹ ¸ðµÎ Àü·Ê ¾ø´Â ÈïºÐÀ» °¨ÃßÁö ¸øÇϰí ÀÖ½À´Ï´Ù.

MCEDÀÇ ¹ßÀü¿¡¼­ ¾×ü »ý°Ë°ú AI´Â ¾î¶² ¿ªÇÒÀ» ÇÒ °ÍÀΰ¡?

MCED ±â¼úÀÇ ÇÙ½ÉÀº ¾×ü »ý°Ë°ú ÀΰøÁö´ÉÀÇ ÅëÇÕÀÔ´Ï´Ù. ÀÌ µÎ °¡Áö Çõ½Å ±â¼úÀº ´ÙÁß¾Ï °ËÁøÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù. ±âÁ¸ÀÇ Á¶Á÷ »ý°ËÀº È¿°úÀûÀÌÁö¸¸ ħ½ÀÀûÀÌ°í ºñ¿ëÀÌ ¸¹ÀÌ µé¸ç, ƯÁ¤ ¾ÏÁ¾¿¡ ±¹ÇѵǴ °æ¿ì°¡ ¸¹½À´Ï´Ù. ¹Ý¸é, ¾×ü »ý°ËÀº ÃÖ¼Òħ½ÀÀûÀ̸ç, Ç÷·ù ³» Á¾¾ç À¯·¡ À¯ÀüÀÚ ´ÜÆíÀ» È®ÀÎÇÏ¿© ±¤¹üÀ§ÇÑ ¾ÏÀ» °ËÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ÁøÇàµÇ±â Àü±îÁö´Â Áø´ÜÀÌ ¾î·Á¿î ÃéÀå, ³­¼Ò, ½Äµµ ¾Ç¼ºÁ¾¾ç µî °ËÁøÀÌ ¾î·Á¿î ¾ÏÀ» ¹ß°ßÇϴµ¥ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. AI¸¦ ÅëÇÑ ÆÐÅÏ ÀνÄÀº ¹æ´ëÇÑ À¯ÀüÀÚ, ´Ü¹éÁúüÇÐ, ´ë»ç ¸¶Ä¿ÀÇ µ¥ÀÌÅͼ¼Æ®¸¦ ºü¸£°Ô ºÐ¼®ÇÏ¿© ¾ç¼º ½ÅÈ£¿Í ¾Ç¼º ½ÅÈ£¸¦ ±¸ºÐÇÔÀ¸·Î½á MCEDÀÇ ÈûÀ» ´õ¿í ÁõÆø½Ãŵ´Ï´Ù. ¼ö¹é¸¸ °³ÀÇ È¯ÀÚ »ùÇÃ·Î ÈÆ·ÃµÈ AI ¸ðµ¨Àº Áø´Ü Á¤È®µµ¸¦ ³ôÀ̰í, À§¾ç¼º ¹× À§À½¼ºÀ» ÃÖ¼ÒÈ­Çϸç, °ËÃâµÈ ¾ÏÀÇ ¹ß»ý Á¶Á÷À» ¿¹ÃøÇÒ ¼ö ÀÖ½À´Ï´Ù. MCED¿¡ AI°¡ È®´ë Àû¿ëµÊ¿¡ µû¶ó ¾Ë°í¸®ÁòÀÌ »õ·Î¿î ¾Ï ¾ÆÇüÀ» ÀνÄÇÏ°í »õ·Î¿î ºÐÀÚ ¹ß°ß¿¡ ÀûÀÀÇÒ ¼ö ÀÖµµ·Ï ÁøÈ­ÇÏ´Â Áö¼ÓÀûÀÎ ÇнÀÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ƯÈ÷ GRAIL, Guardant Health, Exact Sciences µîÀÇ ±â¾÷µéÀº AI¸¦ Ȱ¿ëÇÑ ¾×ü »ý°Ë °Ë»çÀÇ »óǰȭ¿¡ ¾ÕÀå¼­°í ÀÖÀ¸¸ç, ±× À¯È¿¼ºÀ» µÞ¹ÞħÇÏ´Â ±¤¹üÀ§ÇÑ ÀÓ»ó °ËÁõÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÌ ÁÖ¿ä MCED °Ë»ç¿¡ ȹ±âÀûÀÎ ÁöÁ¤À» ºÎ¿©ÇÏ´Â µî ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº ¾Ï °ËÁø¿¡ ´ëÇÑ Á¢±Ù ¹æ½ÄÀÇ ÆÐ·¯´ÙÀÓ ÀüȯÀ» ½Ã»çÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÌ ¼º¼÷ÇØÁü¿¡ µû¶ó ÀÏ»óÀûÀÎ °Ç°­°ËÁø¿¡ ÅëÇÕÇÏ´Â °ÍÀÌ ¿¹¹æ ÀÇÇÐÀÇ »õ·Î¿î Ç¥ÁØÀÌ µÇ¾î Á¶±â ¹ß°ßÀÌ ºñ¿ë È¿À²ÀûÀÎ »ý¸íÀ» ±¸ÇÏ´Â Àü·«À¸·Î º¯¸ðÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ÀÇ·á Á¤Ã¥°ú ½ÃÀå ÅõÀÚ´Â ¾î¶»°Ô MCED äÅÃÀ» °¡¼ÓÈ­Çϰí Àִ°¡?

Á¤ºÎ Á¤Ã¥, ÇコÄɾî ÀÎÇÁ¶ó, ÅõÀÚ µ¿ÇâÀº MCED ½ÃÀå µµÀÔÀÇ ±Ëµµ¸¦ Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ ¸»±â ¾Ï Ä¡·áÀÇ °æÁ¦Àû ºÎ´ã¿¡ ´ëóÇÏ´Â °¡¿îµ¥, Á¶±â ¹ß°ß Àü·«ÀÇ ºñ¿ë È¿À²¼º¿¡ ´ëÇÑ °ø°¨´ë°¡ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. ÀϺΠ±¹°¡ÀÇ ÀÇ·á±â°ü°ú º¸Çè»çµéÀº MCED °Ë»ç°¡ ȯÀÚÀÇ »ýÁ¸À²À» Çâ»ó½ÃŰ¸é¼­ Àüü ¾Ï Ä¡·á ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ´Ù´Â Á¡À» ÀÎÁ¤Çϰí, MCED °Ë»ç¿¡ ´ëÇÑ »óȯ ¸ðµ¨À» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹¿¡¼­´Â Medicare Multi-Cancer Early Detection Screening Coverage Act¿Í °°Àº ÀÔ¹ýÀû ³ë·ÂÀ¸·Î °íÀ§Ç豺ÀÇ MCED Áø´Ü¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î, À¯·´ À§¿øÈ¸ÀÇ ¾Ï °èȹÀº Á¶±â ¹ß°ß¿¡ ´ëÇÑ ³ë·ÂÀ» ¿ì¼±½ÃÇÏ°í ¾×ü »ý°ËÀ» ±â¹ÝÀ¸·Î ÇÑ °ËÁøÀ» ±¹°¡ °Ç°­ °ü¸® ÇÁ·Î±×·¥¿¡ ÅëÇÕÇÏ´Â °ÍÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. Á¤Ã¥ ÁÖµµÀÇ ³ë·Â»Ó¸¸ ¾Æ´Ï¶ó MCED ºÐ¾ß¿¡ ´ëÇÑ º¥Ã³ ijÇÇÅаú »ç¸ðÆÝµå ÅõÀÚÀÇ À¯ÀÔµµ ±â¼ú ¹ßÀü°ú ½ÃÀå È®´ë¸¦ °¡¼ÓÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¾÷°è º¸°í¼­¿¡ µû¸£¸é, MCED ¼Ö·ç¼ÇÀ» °³¹ßÇÏ´Â Á¤¹Ð Á¾¾çÇÐ ½ºÅ¸Æ®¾÷¿¡ ´ëÇÑ ÀÚ±Ý Áö¿øÀº Áö³­ 5³â µ¿¾È ±Þ°ÝÈ÷ Áõ°¡ÇßÀ¸¸ç, ¼ö½Ê¾ï ´Þ·¯ÀÇ Æò°¡¾×Àº ÀÌ ±â¼úÀÇ ÆÄ±«ÀûÀÎ ÀáÀç·Â¿¡ ´ëÇÑ ÅõÀÚÀÚµéÀÇ ½Å·Ú¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ´ëÇü Á¦¾à»çµéµµ MCED Á¦Ç°ÀÇ °øµ¿ °³¹ß ¹× »ó¿ëÈ­¸¦ À§ÇØ »ý¸í°øÇÐ ±â¾÷µé°ú Àü·«Àû Á¦ÈÞ¸¦ ¸Î°í ¿¬±¸¿Í Çõ½Å¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ±àÁ¤ÀûÀÎ Ãß¼¼¿¡µµ ºÒ±¸Çϰí, ±ÔÁ¦ Ç¥ÁØÈ­, °Ë»ç ±¸¸Å ¿ëÀ̼º, ÀÏ¹Ý ´ëÁßÀÇ ÀÎ½Ä µîÀÇ °úÁ¦´Â ¿©ÀüÈ÷ ´ë·® µµÀÔÀÇ À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¾÷°è ÀÌÇØ°ü°èÀÚ, Á¤Ã¥ ÀÔ¾ÈÀÚ, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üÀÇ Çù·ÂÀû ³ë·ÂÀ» ÅëÇØ ÀÌ·¯ÇÑ Àå¾Ö¹°À» ÇØ°áÇÏ´Â °ÍÀº MCED°¡ ¾Ï Á¶±â ¹ß°ßÀ» À§ÇÑ ±¤¹üÀ§ÇÏ°í °øÆòÇÑ ¼Ö·ç¼ÇÀÌ µÉ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

MCEDÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

¼¼°è ´ÙÁß¾Ï Á¶±â ¹ß°ß ½ÃÀåÀÇ ¼ºÀåÀº ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü, Á¤¹ÐÀÇ·áÀÇ Ã¤Åà Ȯ´ë, Àü ¼¼°è ¾Ï ºÎ´ã Áõ°¡ µî ¿©·¯ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS)°ú µðÁöÅÐ PCRÀÇ ±â¼úÀû Çõ½ÅÀº MCED °Ë»çÀÇ ¹Î°¨µµ¿Í ƯÀ̵µ¸¦ Å©°Ô Çâ»ó½ÃÄÑ ¾Ï Á¶±â ¹ß°ßÀÇ ½Å·Ú¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. AI¿Í ºòµ¥ÀÌÅÍ ºÐ¼®À» Áø´Ü ¿öÅ©Ç÷ο쿡 ÅëÇÕÇÏ¿© ¹ÙÀÌ¿À¸¶Ä¿ Ž»öÀ» °£¼ÒÈ­ÇÏ°í ¾Ï ½Ã±×´Ïó¸¦ ½Å¼ÓÇϰí Á¤È®ÇÏ°Ô ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¶ÇÇÑ, °³ÀÎÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó Ä¡·á¿Í ½ºÅ©¸®´×À» ÇÏ´Â ¸ÂÃãÇü ÀÇ·á·ÎÀÇ ÀüȯÀº °í±Þ MCED ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾Ï Á¶±â ¹ß°ßÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ȯÀÚµéÀÌ Àû±ØÀûÀÎ °Ç°­ °ü¸® ¿É¼ÇÀ» Ãß±¸ÇÏ°Ô µÇ¸é¼­ ¼ÒºñÀÚ Çൿµµ Áß¿äÇÑ ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, DTC(Direct-to-Consumer : ¼ÒºñÀÚ Á÷Á¢ ÀÇ·Ú) À¯ÀüÀÚ °Ë»çÀÇ º¸±ÞÀÌ È®»êµÇ°í ÀÖ´Â °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, °³ÀεéÀÌ °³Àκ° ¸ÂÃãÇü °Ç°­ ¸ð´ÏÅ͸µ Àü·«ÀÇ ÀÏȯÀ¸·Î MCED °Ë»ç¸¦ ¼±ÅÃÇϰí ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµ Ãø¸é¿¡¼­ º´¿ø, Áø´Ü ½ÇÇè½Ç, ¿¬±¸±â°üÀº MCED ±â¼úÀ» äÅÃÇÏ´Â ÁÖ¿ä äÅÃÀÚÀ̸ç, ÀÏ»óÀûÀÎ ¾Ï °ËÁø ÇÁ·Î±×·¥¿¡ ÀÌ·¯ÇÑ °Ë»ç¸¦ ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. µ¿¹ÝÁø´Ü, Ä¡·á ¸ð´ÏÅ͸µ µî Á¾¾çÇÐ ¿Ü¿¡µµ MCEDÀÇ Àû¿ëÀÌ È®´ëµÇ°í ÀÖ¾î ½ÃÀå ±âȸ´Â ´õ¿í ³Ð¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Ï »ç¸Á·üÀ» ³·Ãß±â À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê´Â MCEDÀÇ Ã¤ÅÃÀ» Áö¿øÇÏ´Â Á¤Ã¥Àû ÇÁ·¹ÀÓ¿öÅ©¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÅÈï±¹¿¡¼­´Â ÀÇ·á ÀÎÇÁ¶ó °³¼±°ú °¡Ã³ºÐ ¼Òµæ Áõ°¡¿¡ ÈûÀÔ¾î ÷´Ü Áø´Ü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ¼ºÀåÀÌ ±â´ëµÇ´Â ¹Ý¸é, ±ÔÁ¦ÀÇ º¹À⼺, À¯ÀüÀÚ °Ë»ç¸¦ µÑ·¯½Ñ À±¸®Àû °í·Á, ´ë±Ô¸ð °ËÁõ ¿¬±¸ÀÇ Çʿ伺 µîÀÇ ¹®Á¦¸¦ ÇØ°áÇÏÁö ¾ÊÀ¸¸é Àå±âÀûÀΠäÅÃÀ» À¯ÁöÇÒ ¼ö ¾ø½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí, ±â¼ú Çõ½ÅÀÌ ÇѰ迡 µµÀüÇÏ´Â °¡¿îµ¥ MCED´Â ¹Ì·¡ÀÇ ¾Ï ¿¹¹æ°ú Á¶±â °³ÀÔÀÇ Ãʼ®ÀÌ µÉ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(À¯ÀüÀÚ ÆÐ³Î & LDT, ¾×ü »ý°Ë), ÃÖÁ¾ ¿ëµµ(º´¿ø, ¿¬±¸±â°ü, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

ÀϹÝÀûÀ¸·Î ÁøÇàµÇ´Â LLM ¹× ¾÷°è ƯȭÇü SLM¿¡ ´ëÇÑ Äõ¸®¿¡ ÀÇÁ¸ÇÏ´Â ´ë½Å ¿ì¸®´Â ¼¼°è µµ¸ÞÀÎ Àü¹®°¡°¡ ¾ö¼±ÇÑ ÄÁÅÙÃ÷¸¦ Áý¾àÇÑ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù. ¿©±â¿¡´Â ºñµð¿À ³ìÃë·Ï, ºí·Î±×, °Ë»ö ¿£ÁøÀ» ÀÌ¿ëÇÑ Á¶»ç, ¹æ´ëÇÑ ±â¾÷ µ¥ÀÌÅÍ, Á¦Ç° ¹× ¼­ºñ½º Á¤º¸, ½ÃÀå µ¥ÀÌÅͰ¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

¿ì¸®´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç°°ú OEM)¿¡ µû¸¥ ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Multi Cancer Early Detection Market to Reach US$2.6 Billion by 2030

The global market for Multi Cancer Early Detection estimated at US$1.1 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. Gene Panel & LDT, one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Liquid Biopsy segment is estimated at 18.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$296.0 Million While China is Forecast to Grow at 20.4% CAGR

The Multi Cancer Early Detection market in the U.S. is estimated at US$296.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$556.8 Million by the year 2030 trailing a CAGR of 20.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 13.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR.

Global Multi-Cancer Early Detection Market - Key Trends & Drivers Summarized

How is Multi-Cancer Early Detection Reshaping Oncology Diagnostics?

The landscape of cancer detection is undergoing a seismic shift with the advent of Multi-Cancer Early Detection (MCED) technologies, a breakthrough that promises to revolutionize oncology diagnostics. Unlike conventional cancer screenings that target only a handful of malignancies-such as mammograms for breast cancer or colonoscopies for colorectal cancer-MCED tests utilize advanced genomic, epigenomic, and proteomic biomarkers to simultaneously detect multiple cancer types in a single assay. This is achieved through liquid biopsies, which analyze circulating tumor DNA (ctDNA), RNA signatures, and other molecular alterations in blood samples. As cancer remains a leading global cause of mortality, early detection is critical to improving survival rates. According to the World Health Organization (WHO), late-stage diagnoses account for a substantial proportion of cancer-related deaths, highlighting the urgent need for early, non-invasive, and comprehensive screening solutions. With artificial intelligence (AI) and machine learning (ML) algorithms enhancing biomarker identification, MCED tests are now more accurate, scalable, and accessible than ever before. Several biotech firms and research institutions have made significant strides in validating these tests through large-scale clinical trials, demonstrating their potential to identify cancers even before symptoms appear. The promise of reducing the burden of late-stage cancer diagnoses and improving patient outcomes has generated unprecedented excitement in the medical community, investors, and regulatory agencies alike.

What Role Do Liquid Biopsies and AI Play in Advancing MCED?

At the core of MCED technology lies the integration of liquid biopsies and artificial intelligence, two game-changing innovations that have significantly elevated the accuracy and efficiency of multi-cancer screening. Traditional tissue biopsies, while effective, are often invasive, expensive, and limited to specific cancer types. Liquid biopsies, in contrast, offer a minimally invasive alternative that can detect a broad spectrum of cancers by identifying tumor-derived genetic fragments in the bloodstream. This technique has been particularly beneficial in detecting hard-to-screen cancers, such as pancreatic, ovarian, and esophageal malignancies, which often remain undiagnosed until advanced stages. AI-driven pattern recognition further amplifies the power of MCED by rapidly analyzing vast datasets of genetic, proteomic, and metabolic markers to differentiate between benign and malignant signals. AI models trained on millions of patient samples can refine diagnostic accuracy, minimize false positives and negatives, and even predict the tissue of origin for detected cancers. The growing adoption of AI in MCED has also enabled continuous learning, where algorithms evolve to recognize emerging cancer subtypes and adapt to new molecular discoveries. Notably, companies such as GRAIL, Guardant Health, and Exact Sciences have spearheaded efforts in commercializing AI-powered liquid biopsy tests, with extensive clinical validation backing their efficacy. Furthermore, regulatory approvals, such as the breakthrough designation granted by the U.S. Food and Drug Administration (FDA) for leading MCED tests, signal a paradigm shift in how cancer screening is approached. As these technologies mature, their integration into routine health check-ups is expected to become a new standard in preventive medicine, transforming early detection into a cost-effective, life-saving strategy.

How Are Healthcare Policies and Market Investments Accelerating MCED Adoption?

Government policies, healthcare infrastructure, and investment trends play a pivotal role in shaping the trajectory of MCED market adoption. As healthcare systems worldwide grapple with the economic burden of late-stage cancer treatments, there is growing consensus on the cost-effectiveness of early detection strategies. Several national health agencies and insurance providers are exploring reimbursement models for MCED tests, acknowledging their potential to reduce overall cancer treatment costs while improving patient survival rates. In the United States, for instance, legislative efforts such as the Medicare Multi-Cancer Early Detection Screening Coverage Act aim to expand access to MCED diagnostics among high-risk populations. Similarly, the European Commission’s Cancer Plan has prioritized early detection initiatives, pushing for greater integration of liquid biopsy-based screenings into national healthcare programs. Beyond policy-driven efforts, the influx of venture capital and private equity investments in the MCED sector has been instrumental in accelerating technological advancements and market expansion. According to industry reports, funding for precision oncology startups developing MCED solutions has surged dramatically over the past five years, with multi-billion-dollar valuations reflecting investor confidence in the technology’s disruptive potential. Leading pharmaceutical giants have also entered strategic partnerships with biotech firms to co-develop and commercialize MCED products, further fueling research and innovation. However, despite these positive trends, challenges such as regulatory standardization, test affordability, and public awareness remain barriers to mass adoption. Addressing these hurdles through collaborative efforts between industry stakeholders, policymakers, and healthcare providers will be crucial in ensuring MCED becomes a widespread and equitable solution for early cancer detection.

What Are the Key Market Drivers Shaping the Future of MCED?

The growth in the global Multi-Cancer Early Detection market is driven by several factors, including rapid technological advancements, increasing adoption of precision medicine, and the rising burden of cancer worldwide. Technological breakthroughs in next-generation sequencing (NGS) and digital PCR have significantly enhanced the sensitivity and specificity of MCED tests, making them more reliable for early-stage cancer detection. The integration of AI and big data analytics into diagnostic workflows has also streamlined biomarker discovery, allowing for faster and more accurate identification of cancer signatures. Additionally, the shift toward personalized medicine, where treatments and screenings are tailored to individual genetic profiles, has fueled demand for advanced MCED solutions. Consumer behavior is another critical driver, as awareness about the benefits of early cancer detection grows and patients increasingly seek proactive healthcare options. The rising prevalence of direct-to-consumer (DTC) genetic testing has also contributed to market expansion, with individuals opting for MCED tests as part of their personalized health monitoring strategies. From an end-use perspective, hospitals, diagnostic laboratories, and research institutions are among the key adopters of MCED technologies, integrating these tests into routine cancer screening programs. The expanding applications of MCED beyond oncology-such as in companion diagnostics and treatment monitoring-have further broadened market opportunities. Additionally, government initiatives aimed at reducing cancer mortality rates have driven policy frameworks that support MCED adoption. Emerging economies are also witnessing a surge in demand for advanced diagnostics, fueled by improving healthcare infrastructure and increasing disposable incomes. While market growth is promising, challenges such as regulatory complexities, ethical considerations surrounding genetic testing, and the need for large-scale validation studies must be addressed to sustain long-term adoption. Nevertheless, as innovation continues to push boundaries, MCED is poised to become a cornerstone in the future of cancer prevention and early intervention.

SCOPE OF STUDY:

The report analyzes the Multi Cancer Early Detection market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Gene Panel & LDT, Liquid Biopsy); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â